<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225052</url>
  </required_header>
  <id_info>
    <org_study_id>YHP1903-101</org_study_id>
    <nct_id>NCT04225052</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, crossover clinical trial to evaluate the safety and
      pharmacokinetics of YHP1903 in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      32 healthy subjects wil be randomized one of 2 groups in the same ratio. Subjects in group 1
      will be administered &quot;comparator&quot; and &quot;YHP1903&quot; by cross-over design on day1, 8.

      Subjects in group 2 will be administered &quot;YHP1903&quot; and &quot;comparator&quot; by cross-over design on
      day1, 8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Actual">January 14, 2020</completion_date>
  <primary_completion_date type="Actual">January 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0-96 hours</time_frame>
    <description>AUCt of Varenicline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-96 hours</time_frame>
    <description>Cmax of Varenicline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0-96 hours</time_frame>
    <description>AUCinf of Varenicline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0-96 hours</time_frame>
    <description>Tmax of Varenicline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>0-96 hours</time_frame>
    <description>t1/2 of Varenicline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>16 subjects, Cross-over, Single dose of comparator on day1, Single dose of YHP1903 on day8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>16 subjects, Cross-over, Single dose of YHP1903 on day1, Single dose of comparator on day8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHP1903</intervention_name>
    <description>YHP1903 Tab. 1mg</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Champix</intervention_name>
    <description>Comparator Champix Tab. 1mg</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male/female aged 19 to 55 with body mass index(BMI) between 18.5 and 30kg/m2

          2. Acceptable medical history, physical examination, laboratory tests and EKG, during
             screening

          3. Subjects who has signed a written informed consent voluntarily,prior to any procedure,
             using a form that is approved by the local Institutional Review Board after detail
             explanation of the purpose, contents, and characteristic of the drug

        Exclusion Criteria:

          1. History of clinically significant disease

          2. Sitting blood pressure meeting the following criteria at screening:

               -  140 ≤ systolic blood pressure ≤90 (mmHg)

               -  90 ≤ diastolic blood pressure ≤ 60 (mmHg)

          3. Have AST(SGOT) or/and ALT(SGPT) &gt; 1.5 times of normal upper limit or Total bilirubin &gt;
             2.0 mg/dl at the time of screening

          4. Volunteers considered not eligible for the clinical trial by the investigator

          5. Administration of other investigational products within 6 month prior to the first
             dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingul Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk national university hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

